In urothelial carcinoma of the bladder, the axis of miR-139-3p/KIF18B/Wnt/β-catenin was demonstrated to be an effective therapeutic target by inhibiting the malignant progression of the tumor (43). Here, KIF18B is linked to bladder transitional cell carcinoma.